Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €105.51 EUR
Change Today +0.88 / 0.84%
Volume 575.0
CG3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
NASDAQ GM
As of 3:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CG3) Snapshot

Open
€103.98
Previous Close
€104.63
Day High
€105.51
Day Low
€103.84
52 Week High
03/20/15 - €119.90
52 Week Low
05/27/14 - €54.83
Market Cap
83.7B
Average Volume 10 Days
1.4K
EPS TTM
--
Shares Outstanding
793.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP (CG3)

celgene corp (CG3) Related Businessweek News

View More BusinessWeek News

celgene corp (CG3) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp (CG3) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.4M
President and Chief Operating Officer
Total Annual Compensation: $767.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $400.0K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $666.5K
President of Global Hematology and Oncology
Total Annual Compensation: $803.3K
Compensation as of Fiscal Year 2014.

celgene corp (CG3) Key Developments

Celgene Corporation Announces Post-Hoc Subgroup Analysis of Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase Ii Trial of GED-0301

Celgene Corporation announced that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients with active Crohn's disease was presented at Digestive Disease Week (DDW) in Washington, D.C. The primary findings of the phase II trial, which enrolled 166 adult patients with active Crohn’s disease, defined as Crohn’s Disease Activity Index (CDAI) scores >220 to =400, were published in the March 19, 2015 issue of The New England Journal of Medicine. Patients in the trial were treated for two weeks with either placebo or one of three doses of GED-0301 (10 mg, 40 mg or 160 mg tablets, once daily) and then followed for an additional 10 weeks. The presentation at DDW retrospectively examined certain subgroups of patients in the trial. In the subgroup analysis, patients were grouped by disease duration (<5 years vs. =5 years), baseline CDAI score (<260 vs. =260) and baseline levels of the C-reactive protein (CRP) inflammatory marker (<3 mg/L vs. =3 mg/L). Patients in these subgroups were then analyzed for clinical remission (a CDAI score <150) and clinical response (CDAI score reduction =100 points from baseline) at weeks 2 and 4. Clinical remission rates for patients treated with GED-0301 160 mg were similar regardless of disease duration or baseline CDAI or CRP levels and were higher than those for patients on placebo (remission rates ranged from 62.5% to 75% for GED-0301 160 mg vs. 5% to 24% for placebo). These findings provide a rationale for continued evaluation of the 160 mg dose in the phase III program. For patients with a disease duration of at least five years (mean of 15.4 years), 62.5% (15/24) of those treated with GED-0301 160 mg were in clinical remission at week 2, compared with 15.4% (4/26) of those treated with placebo. Similar results were observed at week 4 (66.7% [16/24] vs. 15.4% [4/26], respectively). Clinical response rate was 70.8% (17/24) with GED-0301 160 mg, compared with 19.2% (5/26) with placebo, at week 2 and 79.2 % (19/24) versus 26.9% (7/26), respectively, at week 4. For patients with baseline CDAI of at least 260 (median of 303), 62.5% (10/16) of those treated with GED-0301 160 mg were in clinical remission at week 2, compared with 13.6% (3/22) for placebo and 75.0% (12/16) versus 4.5% (1/22), respectively, at week 4. Clinical response rate was 87.5% (14/16) with GED-0301 160 mg versus 22.7 % (5/22) for placebo at week 2 and 87.5 % (14/16) versus 22.7 % (5/22), respectively, at week 4. Similar results were observed for patients with baseline CRP of at least 3 mg/L (about 60% of patients in the trial). At week 2, 71.4% (20/28) of patients in the GED-0301 160 mg group achieved clinical remission compared with 24.0% (6/25) in the placebo group. At week 4, similar results were observed (75.0% [21/28] vs. 12.0% [3/25]). In the GED-0301 160 mg group, 60.7% (17/28) and 64.3 % The rates of patients with at least one adverse event (AE) were 49%, 62% and 49% for the GED-0301 10 mg, 40 mg and 160 mg doses, respectively, and 67% for placebo. The most commonly reported AEs in the GED-0301 treatment groups were abdominal pain (10-12%), Crohn’s disease worsening (10-15%), urinary tract infection (5-15%) and CRP increase (5-9%). The rates of serious AEs in the GED-0301 groups were 7%, 2% and 2% for 10 mg, 40 mg and 160 mg dose, respectively, compared with 2% for placebo.

Celgene Corporation Seeks Acquisitions

Celgene Corporation (NasdaqGS:CELG) is seeking acquisitions. Jackie Fouse, President, Global Hematology and Oncology, said, "We have also got what I like to call a little M&A pipeline within a pipeline, so to speak, because we have options to acquire many of our partner companies." Fouse added, "I think the possibility for us to do what we probably characterize as bolt-on acquisitions is still there."

Celgene Corporation Announces Results from A Pre-Specified Secondary Endpoint Analysis of MDS-005

Celgene Corporation announced results from a pre-specified secondary endpoint analysis of MDS-005, a multicenter, randomized, placebo controlled phase III study of REVLMID (lenalidomide) compared with placebo in patients with non-del-5q myelodysplastic syndromes (MDS). The analysis was presented during the 13th International Symposium on Myelodysplastic Syndromes. Results from MDS-005 were originally presented at the 2014 American Society of Hematology annual meeting and reported that significantly more patients treated with lenalidomide achieved red-blood-cell-transfusion independence (RBC-TI) of at least 56 days compared with placebo (26.9%, [43/160 patients] vs. 2.5%, [2/79 patients]. In the United States, REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma. REVLIMID is also approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand. REVLIMID is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities and in Europe for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. In addition, REVLIMID is approved in the United States for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. U.S. Regulatory Information for REVLIMID REVLIMID (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of patients with multiple myeloma (MM) REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1 "risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib REVLIMID is not indicated and not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €105.51 EUR +0.88

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $398.68 USD -2.47
Bristol-Myers Squibb Co $68.30 USD -0.59
Eli Lilly & Co $74.30 USD +0.03
Medtronic PLC $77.82 USD -0.59
Shire PLC 5,540 GBp +35.00
View Industry Companies
 

Industry Analysis

CG3

Industry Average

Valuation CG3 Industry Range
Price/Earnings 39.7x
Price/Sales 11.6x
Price/Book 13.7x
Price/Cash Flow 34.2x
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.